FDX1 acted as a biomarker for elesclomol due to the FDX1 activity and promoted mitochondria-dependent energy metabolism inducing the toxic effect of elesclomol in tumor cells (Tsvetkov et al., 2019). Here, FDX1 is linked to neoplasm.